Гендерные особенности эффективности гиполипидемической терапии у пациентов с метаболическим синдромом

Objective. Rate lipid-correction effect, the effect on C-reactiveprotein (CRP), intima-media thickness (IMT) and the remodeling of the left ventricle (LV) of lipid-lowering therapy in men and women with metabolic syndrome (MS). Materials. 1172patients with MS (81 male and 91 female), median age 59 (52-67) years. Allpatients were assigned to simvastatin 20 mg daily, sufficient to reach the level of low density lipoprotein cholesterol (LDL-C) in 29 patients. The remainingpatients were randomised into two groups: the first group, the dose of simvastatin was increased to 40 mg daily, patients second group was assigned the combination of simvastatin 20 mg and 10 mg ezetimibe. Methods. Biochemical tests — lipidprofile, CRP was assessed at baseline and at 1, 2 and 6 months. Echocardiography and Doppler ultrasound IMT of the carotid arteries was performed before and after 6 months of treatment Results. Monotherapy with simvastatin 40 mg daily provided the achievement of the target level of LDL cholesterol in 81.2% of men and 55.9% of women (p